Systemic corticosteroids in infant bronchiolitis: A meta-analysis

• Published in: Pediatrics (Evanston) 2000-04, Vol.105 (4), p.E44-e44
• Main Authors: Garrison, M M, Christakis, D A, Harvey, E, Cummings, P, Davis, R L
• Format: Article
• Language: English
• Subjects: Anti-Inflammatory Agents - therapeutic use; Bronchiolitis - drug therapy; Data Interpretation, Statistical; Glucocorticoids - therapeutic use; Humans; Infant; Length of Stay; Pediatrics; Randomized Controlled Trials as Topic; Severity of Illness Index; Steroids
• ISSN: 0031-4005; 1098-4275
• DOI: 10.1542/peds.105.4.e44

To determine whether corticosteroids are efficacious in treating bronchiolitis in hospitalized infants. Online bibliographic databases (Medline, Embase, and Cochrane Clinical Trials Registry) were searched for: 1) bronchiolitis or respiratory syncytial virus, and 2) corticosteroid or glucocorticoid or steroidal antiinflammatory agents or adrenal cortex hormones. Reference lists from all selected articles were also examined. Randomized, placebo-controlled trials of systemic corticosteroids in treatment of infants hospitalized with bronchiolitis were selected by 2 investigators. Of 12 relevant publications identified in the literature search, 6 met the selection criteria and had relevant data available. Investigators independently extracted data for 3 outcomes: length of stay (LOS), duration of symptoms (DOS), and clinical scores. In the pooled analysis, infants who received corticosteroids had a mean LOS or DOS that was.43 days less than those who received the placebo treatment (95% confidence interval: -.81 to -.05 days). The effect size for mean clinical score was -1.60 (95% confidence interval: -1.92 to -1.28), favoring treatment. Secondary analyses of mean LOS or DOS were performed on 5 trials that had clearly identified methods of randomization, 5 trials that measured LOS, and 4 trials that clearly excluded infants with previous wheezing. The estimates of effect were similar to the primary analysis but were not statistically significant. Combined, published reports of the effect of systemic corticosteroids on the course of bronchiolitis suggest a statistically significant improvement in clinical symptoms, LOS, and DOS.